This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.
REGN vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. RGEN: Which Stock Is the Better Value Option?
Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?
by Zacks Equity Research
Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.
Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth
by Zacks Equity Research
Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.
If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
by Zacks Equity Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
by Zacks Equity Research
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
Ocular (OCUL) Announces Positive Data on Wet AMD Candidate
by Zacks Equity Research
Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acuity.
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSEW
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
by Zacks Equity Research
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
by Zacks Equity Research
The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.
Intellia (NTLA) Reports Positive Results for CRISPR Candidates
by Zacks Equity Research
Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
by Zacks Equity Research
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
by Zacks Equity Research
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
Company News for Sep 9, 2022
by Zacks Equity Research
Companies in The News Are: REGN, JPM, CASY, GME
Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success
by Zacks Equity Research
Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
by Zacks Equity Research
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
Regeneron (REGN) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPGP
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why
by Zacks Equity Research
Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.
Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab
by Zacks Equity Research
Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.
Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down
by Zacks Equity Research
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.